Literature DB >> 9578045

Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine.

R G Beran1, R J Gibson.   

Abstract

PURPOSE: Lamotrigine (LTG) is a valuable addition to the medical management of epilepsy with wide spectrum of efficacy and good outcomes for quality of life. We report the emergence of a syndrome of aggressive behavior provoked by LTG in patients with epilepsy and intellectual challenge.
METHODS: On recognition of a tendency to aggression in intellectually challenged patients whose epilepsy was treated with LTG, a survey was conducted of those from centers specializing in management of patients with intellectual disability who were treated with LTG. Responses to LTG were sought and patient's behavioral profiles were determined.
RESULTS: Nineteen patients were identified (16 men, 3 women, aged 17-54 years). Five patients discontinued LTG due to unprovoked aggressive behavior subsequent to its use; 2 had aggressive behavior sufficient to justify discontinuation of LTG but required reintroduction to control the epilepsy; 1 required reduction in LTG dosage; 1 had aggression that responded to psychiatric intervention; and 1 had aggression unrelated to LTG. Four patients had behavioral problems other than aggression, 4 had no change in behavior, and the behavior of 1 was improved by LTG treatment.
CONCLUSIONS: LTG may provoke aggressive behavior and violence in intellectually handicapped patients with epilepsy, which may limit its use in such patients. Acknowledgment of the potential for such disturbance justifies greater surveillance of these patients and early discontinuation of LTG if necessary.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578045     DOI: 10.1111/j.1528-1157.1998.tb01373.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  Psychotropic effects of antiepileptic drugs.

Authors:  Siddhartha Nadkarni; Orrin Devinsky
Journal:  Epilepsy Curr       Date:  2005 Sep-Oct       Impact factor: 7.500

Review 2.  Delivery of epilepsy care to adults with intellectual and developmental disabilities.

Authors:  Orrin Devinsky; Miya Asato; Peter Camfield; Eric Geller; Andres M Kanner; Seth Keller; Michael Kerr; Eric H Kossoff; Heather Lau; Sanjeev Kothare; Baldev K Singh; Elaine Wirrell
Journal:  Neurology       Date:  2015-09-30       Impact factor: 9.910

Review 3.  Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 5.  Lamotrigine. A review of its use in childhood epilepsy.

Authors:  C R Culy; K L Goa
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

Review 6.  Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents.

Authors:  Lars Brunbech; Anne Sabers
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  The use of newer anticonvulsants in neuropsychiatric disorders.

Authors:  Edward Kim
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 8.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Psychopathology in people with epilepsy and intellectual disability; an investigation of potential explanatory variables.

Authors:  C A Espie; J Watkins; L Curtice; A Espie; R Duncan; J A Ryan; M J Brodie; K Mantala; M Sterrick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-11       Impact factor: 10.154

Review 10.  Negative effects of antiepileptic drugs on mood in patients with epilepsy.

Authors:  Marco Mula; Josemir W Sander
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.